Matthew Krebs

17PUBLICATIONS
118CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsMolecular targetsSolid tumoursPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Mar 31, 2026
Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC.

Juanita S Lopez, Kevin J Harrington, Seock-Ah Im

|Feb 19, 2026
Current Insights and Future Directions of Multiomic and Spatial-Omic Analysis in Non-Small Cell Lung Cancer.

Matt Church, Gayle Marshall, Matthew G Krebs

|Jan 07, 2026
Procedures of data merging in precision cancer medicine: the PRIME-ROSE project.

Henk Van der Pol, Tina Kringelbach, Maria Martin Agudo

|Jul 09, 2025
Single-Agent Divarasib in Patients With KRAS G12C-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study.

Adrian G Sacher, Wilson H Miller, Manish R Patel

|Mar 06, 2025
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.

R C Coombes, Sacha Howell, Simon R Lord

|Jul 12, 2024
Eftilagimod Alpha (Soluble LAG3 Protein) Combined with Pembrolizumab as Second-Line Therapy for Patients with Metastatic Head and Neck Squamous Cell Carcinoma.

Martin Forster, Irene Brana, Antonio L Pousa

Pageof 3

Frequent Collaborators

3 joint publications

Simak Ali

3 joint publications

Patrick Ward

3 joint publications

Simon R Lord

3 joint publications

William Gradishar